Top 7 Fastest Growing Pharma & Biotech Companies in Asia for 2026

Key Takeaways

• SillaJen secured FDA IND for oncolytic virus BAL0891 combo
• Oscotec’s lazertinib royalties drove 193% revenue jump to $24.9M
• D&D Pharmatech raised $165M via convertible bond, partnered with Pfizer
• ABL Bio signed up to $2.6B Grabody platform deal with Eli Lilly
• GNI Group completed $300M all‑stock acquisition of Cullgen

Pulse Analysis

Asia’s biotech sector is entering a scaling phase driven by a confluence of robust domestic R&D, supportive government policies, and an influx of foreign capital. The FT’s 2026 high‑growth list captures firms that have turned scientific breakthroughs into commercial traction, with compound annual growth rates exceeding 50% for most. This momentum reflects broader macro trends: rising prevalence of chronic diseases in the region, expanding payer coverage, and a strategic pivot toward platform technologies that can be licensed globally.

The highlighted companies illustrate how cross‑border partnerships are accelerating market entry. Oscotec’s lazertinib royalties and a $1.04 billion Sanofi deal for its tau‑targeting antibody underscore the value of Korean discovery pipelines to multinational pharma. Meanwhile, D&D Pharmatech’s $165 million bond and Pfizer collaboration on oral GLP‑1 therapies demonstrate how Asian firms are leveraging capital markets to fund next‑generation delivery platforms. ABL Bio’s multi‑billion‑dollar Grabody agreement with Eli Lilly and GNI Group’s $300 million acquisition of Cullgen further cement the region’s role as a source of high‑impact assets for global players.

For investors and industry strategists, the data suggest a rebalancing of R&D spend toward Asia, where talent density and cost efficiencies create attractive risk‑adjusted returns. The surge in FDA IND approvals and large‑scale licensing deals indicates that regulatory pathways are becoming more navigable for Asian innovators. As these firms scale, they are likely to drive competitive pressure on legacy Western pipelines, prompting a wave of strategic alliances, joint ventures, and potential M&A activity that could reshape the global pharmaceutical landscape.